The Hub24 Ltd (ASX:HUB) share price has surged by 55.2% since the beginning of 2024, raising questions about whether the stock is now trading at an inflated valuation. In contrast, the ResMed CDI (ASX:RMD) share price has dropped 69.0% from its 52-week low.
HUB Share Price Overview
Founded in 2007, Hub24 has established itself as a prominent player in the wealth management sector. The company offers software and management platforms for financial advice, superannuation, and investment management, including its key products: HUB24, Class, and myprosperity. HUB24’s competitive edge lies in the quality of its services, which have earned it top rankings in various industry reports in 2024.
RMD Share Price Overview
ResMed, founded in 1989 and now based in San Diego, is a global leader in medical equipment for sleep apnea treatment. The company operates in over 140 countries and offers products and services in Sleep and Respiratory Care, as well as Software as a Service (SaaS) for out-of-hospital care. ResMed’s cloud-connected devices and digital health network provide valuable data to enhance patient outcomes and reduce healthcare costs.
Valuation Insights
For Hub24 Ltd, the current price-to-sales ratio stands at 16.30x, significantly higher than its 5-year average of 10.64x, suggesting that the stock is trading above its historical norm. Conversely, ResMed's price-to-sales ratio is currently 5.13x, below its 5-year average of 6.13x, indicating that the stock is trading under its historical average. While these metrics offer a snapshot of valuation, they should be complemented with further analysis to form a comprehensive view of each company’s market position and prospects.